# Haemonetics Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Haemonetics Corporation). ## Overview Haemonetics is a U.S.-based medical technology company that designs and sells systems used to collect, process, and manage blood and plasma. Its portfolio spans plasma collection technologies, blood center collection and processing equipment, and hospital products for vascular closure, blood management, and related procedures. ## Products & services • Plasma collection devices and disposables • Donor management software and supporting software • Blood collection and processing systems for centers • Vascular closure and sensor-guided technologies • Hemostasis, cell salvage, and transfusion management • Esophageal protection products - **Plasma** (35%) — Devices, disposables, and software used by plasma centers to collect plasma efficiently and manage donor operations. - **Blood Center** (23%) — Collection and processing systems for blood centers handling plasma, red cells, and platelets. - **Hospital - Interventional Technologies** (22%) — Products used in interventional procedures, including vascular closure, sensor-guided technologies, and esophageal protection. - **Hospital - Blood Management Technologies** (20%) — Products that help hospitals manage bleeding and blood use, including hemostasis, cell salvage, and transfusion management. - Plasma collection devices and disposable kits - Donor management and supporting software solutions - Blood collection and processing devices and disposables - Vascular closure and sensor-guided technologies - Hemostasis management, cell salvage, and transfusion products - Esophageal protection products ## Customers Haemonetics sells primarily to healthcare and blood-collection institutions rather than individual patients. Its main buyers are biopharmaceutical plasma companies, blood collection groups, independent blood centers, hospitals, hospital service providers, group purchasing organizations, and national health organizations. The business is concentrated in a relatively small number of large accounts, especially in Plasma, where customer renewals and pricing decisions can materially affect revenue. - **Plasma collection customers** (primary) — Biopharmaceutical plasma operators buy collection devices, disposables, and software to run donor centers efficiently and reliably. - **Blood centers** (primary) — Independent and institutional blood centers buy collection and processing systems for plasma, red cells, and platelets. - **Hospitals** (primary) — Hospitals buy interventional and blood management products to support procedures, reduce blood loss, and improve workflow. - **Group purchasing organizations** (secondary) — GPOs influence purchasing decisions and contract access for hospital products. - **National health organizations** (secondary) — Public health systems and agencies buy blood collection solutions through tenders and centralized procurement. - Biopharmaceutical plasma companies buy collection systems and disposables - Blood centers buy collection and processing tools for plasma and components - Hospitals buy interventional and blood management products for procedures - Group purchasing organizations influence hospital procurement decisions - National health organizations and public tenders support blood supply programs - Large customer concentration makes renewals and pricing highly important ## Geography Haemonetics generates most of its revenue in the United States, with the remainder coming from international markets across Europe, Japan, and other parts of Asia. In fiscal 2025, the company reported 74.3% of revenue from the U.S., 12.9% from Europe, 4.6% from Japan, 6.8% from Rest of Asia, and 1.4% from Other markets. The company sells in roughly 95-96 countries and is exposed to foreign exchange movements, especially the yen, euro, and yuan. - **United States** (74.3%) - **Europe** (12.9%) - **Japan** (4.6%) - **Rest of Asia** (6.8%) - **Other** (1.4%) - United States is the largest revenue market at 74.3% of fiscal 2025 sales - Europe contributed 12.9% of fiscal 2025 revenue - Japan contributed 4.6% of fiscal 2025 revenue - Rest of Asia contributed 6.8% of fiscal 2025 revenue - Sales span about 95-96 countries through direct and distributor channels - FX exposure is meaningful because international sales are local-currency based ## Strategy Haemonetics is prioritizing the Plasma and Hospital segments, which management believes have the strongest growth potential and best long-term value creation. The company is sharpening its focus in Blood Center toward targeted opportunities, especially plasma and platelets, while continuing to invest in internal development and selective inorganic growth. Capital allocation also includes share repurchases to offset equity dilution and support shareholder returns. - **Expand Plasma and Hospital franchises** (medium-term) — Management sees these as the highest-growth businesses and the main drivers of long-term value. - **Refocus Blood Center on targeted opportunities** (short-term) — Blood Center operates in more challenging markets, so resources are being concentrated on the most attractive niches. - **Invest in product innovation and regulatory execution** (medium-term) — New products and approvals are needed to defend share and keep pace with clinical and technology changes. - **Use capital allocation to support growth and dilution management** (short-term) — Repurchases and disciplined investment help balance shareholder returns with funding for the business. - Focus capital and R&D on Plasma and Hospital growth opportunities - Target Blood Center opportunities in plasma and platelets - Invest in new products, software, and regulatory compliance - Use acquisitions to accelerate long-term growth where attractive - Repurchase shares to offset equity dilution from employee grants - Maintain global commercial reach through direct and distributor channels ## Risks Haemonetics is exposed to customer concentration, especially in Plasma, where a small number of accounts drive a meaningful share of sales and contract renewals can shift quickly. The company also faces regulatory, competitive, and foreign exchange risk because it sells regulated medical products globally and earns a substantial portion of revenue outside the U.S. Accounting and operational results can be affected by demand changes, product approvals, and inventory or rebate estimates. - **Customer concentration and contract non-renewal** [high] — A limited number of Plasma customers account for a material portion of sales, so renewal or pricing changes can quickly affect revenue. - **Regulatory and clinical adoption risk** [high] — Products require approvals and must keep pace with evolving clinical practice and standards. - **Foreign exchange volatility** [medium] — International sales are denominated in local currencies, especially yen, euro, and yuan, creating translation and transaction exposure. - **Competitive pressure** [high] — Large global competitors have substantial resources and similar product offerings, which can affect pricing and market share. - **Cybersecurity and data integrity** [medium] — Medical devices and software handle sensitive patient and customer information and could be targeted by attackers. - Large customer concentration can pressure revenue if contracts are lost or repriced - Plasma demand and customer renewal risk are especially important - Regulatory approvals and changing clinical standards can disrupt product adoption - Foreign exchange swings affect international revenue and margins - Competition from larger medtech peers can compress pricing and share - Cybersecurity and data protection failures could disrupt operations and trust ## Accounting Haemonetics’ reported revenue is sensitive to estimates for rebates, returns, and volume discounts, so revenue recognition depends heavily on management judgment. Inventory provisions, goodwill and intangible asset impairment testing, and foreign currency hedging also matter because demand shifts, product launches, or exchange-rate moves can change reported earnings and asset values. The company’s international mix makes translation effects and hedge accounting relevant to period-to-period comparability. - **Revenue recognition and variable consideration** — Affects reported sales and gross margin - **Inventory excess and obsolescence reserves** — Affects cost of sales and operating profit - **Goodwill and intangible asset impairment** — Affects operating income and balance sheet carrying values - **Foreign currency hedging** — Affects reported earnings and cash flow volatility - Revenue net of rebates, returns, and volume discounts uses management estimates - Upfront rebate payments are capitalized and amortized against revenue - Inventory reserves depend on forecasted demand and product launch timing - Goodwill and intangibles may be impaired if market or customer conditions weaken - Foreign currency hedges affect reported results and cash flow comparability --- *Last updated: 2026-04-28T20:12:52.195186+00:00*